CMMB Chemomab Therapeutics Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: CMMB

Price (delayed)

$0.74

Market cap

$10.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.06

Enterprise value

$1.54M

Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of ...

Highlights
CMMB's EPS is up by 20% since the previous quarter and by 15% year-on-year
CMMB's net income is up by 17% since the previous quarter and by 12% year-on-year
CMMB's quick ratio is down by 30% YoY but it is up by 3.8% from the previous quarter
The debt has soared by 83% YoY
CMMB's equity has plunged by 53% YoY and by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.chemomab.com
Peers: NWBO

Key stats

What are the main financial stats of CMMB
Market
Shares outstanding
14.2M
Market cap
$10.51M
Enterprise value
$1.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$24.22M
EBITDA
-$24.15M
Free cash flow
-$23.61M
Per share
EPS
-$2.06
Free cash flow per share
-$2.01
Book value per share
$1.37
Revenue per share
$0
TBVPS
$1.89
Balance sheet
Total assets
$22.15M
Total liabilities
$5.15M
Debt
$392,000
Equity
$17M
Working capital
$16.06M
Liquidity
Debt to equity
0.02
Current ratio
4.32
Quick ratio
4.32
Net debt/EBITDA
0.37
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-88.5%
Return on equity
-114%
Return on invested capital
-266.7%
Return on capital employed
-139.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CMMB stock price

How has the Chemomab Therapeutics stock price performed over time
Intraday
0%
1 week
15.63%
1 month
-8.3%
1 year
-49.32%
YTD
45.1%
QTD
-5.01%

Financial performance

How have Chemomab Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$25.46M
Net income
-$24.22M
Gross margin
N/A
Net margin
N/A
CMMB's net income is up by 17% since the previous quarter and by 12% year-on-year
Chemomab Therapeutics's operating income has increased by 16% from the previous quarter and by 11% YoY

Growth

What is Chemomab Therapeutics's growth rate over time

Valuation

What is Chemomab Therapeutics stock price valuation
P/E
N/A
P/B
0.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CMMB's EPS is up by 20% since the previous quarter and by 15% year-on-year
CMMB's equity has plunged by 53% YoY and by 6% from the previous quarter
CMMB's price to book (P/B) is 51% less than its 5-year quarterly average of 1.1 and 10% less than its last 4 quarters average of 0.6

Efficiency

How efficient is Chemomab Therapeutics business performance
CMMB's return on equity has dropped by 96% year-on-year and by 2.2% since the previous quarter
The return on assets has dropped by 69% year-on-year
Chemomab Therapeutics's return on invested capital has decreased by 17% QoQ

Dividends

What is CMMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMMB.

Financial health

How did Chemomab Therapeutics financials performed over time
CMMB's total assets is down by 49% year-on-year and by 5% since the previous quarter
CMMB's quick ratio is down by 30% YoY but it is up by 3.8% from the previous quarter
The debt is 98% lower than the equity
CMMB's debt to equity has soared by 100% from the previous quarter and by 100% YoY
The debt has soared by 83% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.